🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Tie presents Phase 2 #coloncancer and #ctDNA based on Dynamic-III for stage 3 pts for a primary endpoint of 2-RFS (goal HR < .746) demonstrates if ctDNA+ 🛑 No statistical diff for dose escalation. #cancer #canceresearch #clinicaltrials

New research from NBCA’s Alok Khorana, MD & Dana Angelini shows DOACs may lower the risk of bleeding, ICU stays & death vs. LMWH in cancer patients with brain metastases. 📍Poster #80 | #ASCO25 | 9 a.m. –12 p.m. 🔗 asco.org/abstracts-pres… 📍Visit NBCA at booth 13000! #StopTheClot

At #ASCO25 Suneel Kamath MD (Cleveland Clinic) discusses critical gaps in cancer research funding equity! How do funding disparities across cancer types create broader inequities in care access, innovation & survival outcomes? What policy reforms could ensure a more equitable

CheckMate 577 as expected shows OS benefit of adjuvant Nivolumab in gastroesophageal cancers is restricted to PD-L1+ group. #ASCO25

💸 Not all cancers are funded equally – in fact, the most LETHAL cancers often receive the LEAST federal research funding 😲 Suneel Kamath MD links underfunding to fewer trials – and fewer advances for the toughest-to-treat cancers Cleveland Clinic #ASCO25 👇 healio.com/news/hematolog…

CLDN18.2 targeted CAR-T cells showing intriguing PFS improvement compared to chemo. Tolerability remains an issue but cell therapy is coming to solid tumors! #ASCO25

Not all cancers are funded equally - in fact, the most lethal cancers get the LEAST funding. As federal money becomes more scarce, ensuring equitable funding across cancers is that much more important. #ASCO25 #CleClinicCancer

Suneel Kamath MD Jame Abraham, MD, FACP Cleveland Clinic MD Alok Khorana, MD This is an important point, highlighting a major imbalance in cancer research funding. It's essential to consider why certain cancers receive less financial support—could it be due to prevalence, public awareness, or mortality rates? Addressing this issue could lead to

#ASCO25 ⛰️MATTERHORN - first ever randomised trial to show a significant benefit for ICI (or any targeted therapy) in operable gastroesophageal cancer. ~10% ⬆️ EFS at 2y EFS is important in a disease where metastases cause real morbidity Happy for my patients!

MATTERHORN is out! 🔹️Perioperative durvalumab+FLOT significantly improves 2-year event-free survival (67.4% vs. 58.5%). 🔹️OS not mature. 🔹️Adverse event rates similar. #ASCO25 nej.md/437IXTF

📸 Caught in the act at #ASCO25 The legend Mark dives deep with Suneel Kamath MD into why the most LETHAL #cancers receive comparatively few research dollars 💸 When you see Mark, you know a big story is about to drop - don’t miss this one! ➡️bit.ly/443Zqrh

Results from the phase 3 DESTINY-Gastric04 trial support T-DXd as second-line standard care for patients with HER2+, metastatic gastric/GEJ cancer, according to Kohei shitara, who presented these results at #ASCO25. #gicsm shorturl.at/ED3RG

Pls join us tomorrow re: #earlyonset #cancer on 6/2 at 8am. #cancerresearch ASCO #ASCO25 Kimryn Rathmell #cancersupport #advocacy

Worthy of a plenary session — CO.21 shows that exercise reduces recurrence after adjuvant and improves OS

Congratulations to 🇨🇦CCTG for this brilliant study- the most impactful at #ASCO2025 for my patients! 👉🏽Interesting to see exercise ⬇️ the risk of recurrence to liver, but lung and peritoneal mets did not appear to be impacted. 👉🏽Exercise reduced risk of new primary

Don’t let your patients overlook the least toxic and costly intervention to improve outcome.

Encouraging results for Zanidatamab+chemo in 1st-line gastroesophageal adenocarcinoma: ♦️ORR: 76% ♦️Median PFS: 12.5 months ♦️Median OS: 36.5 months Look forward to HERIZON-GEA-01 results of chemo + zani +/- tislelizumab! #ASCO25

Thank you 🙏🏾 and congratulations 👏🏽Frank Sinicrope, MD and colleagues Alliance for Clinical Trials in Oncology on #ATOMIC! So relieved we are no longer stuck with only chemo for patients with dMMR #ColonCancer in need of adjuvant therapy. Outstanding example of the life-saving research funded by National Cancer Institute !